Anaplastic lymphoma kinase inhibitors for genetically rearranged non-small cell lung cancer a review of cost-effectiveness and guidelines
Despite the availability of direct and indirect evidence comparing the clinical effectiveness of different anaplastic lymphoma kinase inhibitors (ALKIs), comparative cost-effectiveness of these tyrosine kinase inhibitors (TKIs) is relatively less established, particularly in the first- and second-li...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, November 30, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references